Drugs designed to target HER2-postive breast cancer could also benefit some patients with bile duct cancer, according to results of a patient trial to be presented on Thursday at the 36th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics in Barcelona, Spain. Bile duct cancer is rare, treatment options are limited, and the survival rates are low.
from Medical Xpress - latest medical and health news stories https://ift.tt/LQeWAzo
